Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase - PubMed (original) (raw)
Review
. 2006 Oct 16;25(48):6361-72.
doi: 10.1038/sj.onc.1209882.
Affiliations
- PMID: 17041622
- DOI: 10.1038/sj.onc.1209882
Review
Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase
J Avruch et al. Oncogene. 2006.
Abstract
Target of Rapamycin (TOR), a giant protein kinase expressed by all eucaryotic cells, controls cell size in response to nutrient signals. In metazoans, cell and organismal growth is controlled by nutrients and the insulin/insulin-like growth factor (IGF) system, and the understanding of how these inputs coordinately regulate TOR signaling has advanced greatly in the past 5 years. In single-cell eucaryotes and Caenorhabditis elegans, TOR is a dominant regulator of overall mRNA translation, whereas in higher metazoans, TOR controls the expression of a smaller fraction of mRNAs that is especially important to cell growth. TOR signals through two physically distinct multiprotein complexes, and the control of cell growth is mediated primarily by TOR complex 1 (TORC1), which contains the polypeptides raptor and LST8. Raptor is the substrate binding element of TORC1, and the ability of raptor to properly present substrates, such as the translational regulators 4E-BP and p70 S6 kinase, to the TOR catalytic domain is essential for their TOR-catalysed phosphorylation, and is inhibited by the Rapamycin/FKBP-12 complex. The dominant proximal regulator of TORC1 signaling and kinase activity is the ras-like small GTPase Rheb. Rheb binds directly to the mTOR catalytic domain, and Rheb-GTP enables TORC1 to attain an active configuration. Insulin/IGF enhances Rheb GTP charging through the ability of activated Akt to inhibit the Rheb-GTPase-activating function of the tuberous sclerosis heterodimer (TSC1/TSC2). Conversely, energy depletion reduces Rheb-GTP charging through the ability of the adenosine monophosphate-activated protein kinase to phosphorylate TSC2 and stimulate its Rheb-GTPase activating function, as well as by HIFalpha-mediated transcriptional responses that act upstream of the TSC1/2 complex. Amino-acid depletion inhibits TORC1 acting predominantly downstream of the TSC complex, by interfering with the ability of Rheb to bind to mTOR. The components of the insulin/IGF pathway to TORC1 are now well established, whereas the elements mediating the more ancient and functionally dominant input of amino acids remain largely unknown.
Similar articles
- Rheb binds and regulates the mTOR kinase.
Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. Long X, et al. Curr Biol. 2005 Apr 26;15(8):702-13. doi: 10.1016/j.cub.2005.02.053. Curr Biol. 2005. PMID: 15854902 - The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.
Nobukini T, Thomas G. Nobukini T, et al. Novartis Found Symp. 2004;262:148-54; discussion 154-9, 265-8. Novartis Found Symp. 2004. PMID: 15562827 Review. - Rheb activation of mTOR and S6K1 signaling.
Hanrahan J, Blenis J. Hanrahan J, et al. Methods Enzymol. 2006;407:542-55. doi: 10.1016/S0076-6879(05)07044-8. Methods Enzymol. 2006. PMID: 16757352 - Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression.
Fingar DC, Blenis J. Fingar DC, et al. Oncogene. 2004 Apr 19;23(18):3151-71. doi: 10.1038/sj.onc.1207542. Oncogene. 2004. PMID: 15094765 Review. - Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity.
Finlay GA, Malhowski AJ, Liu Y, Fanburg BL, Kwiatkowski DJ, Toksoz D. Finlay GA, et al. Cancer Res. 2007 Oct 15;67(20):9878-86. doi: 10.1158/0008-5472.CAN-07-1394. Cancer Res. 2007. PMID: 17942919
Cited by
- Human T2D-Associated Gene IMP2/IGF2BP2 Promotes the Commitment of Mesenchymal Stem Cells Into Adipogenic Lineage.
Regué L, Wang W, Ji F, Avruch J, Wang H, Dai N. Regué L, et al. Diabetes. 2023 Jan 1;72(1):33-44. doi: 10.2337/db21-1087. Diabetes. 2023. PMID: 36219823 Free PMC article. - Drosophila as a Model Organism to Study Basic Mechanisms of Longevity.
Ogienko AA, Omelina ES, Bylino OV, Batin MA, Georgiev PG, Pindyurin AV. Ogienko AA, et al. Int J Mol Sci. 2022 Sep 24;23(19):11244. doi: 10.3390/ijms231911244. Int J Mol Sci. 2022. PMID: 36232546 Free PMC article. Review. - The late endosome is essential for mTORC1 signaling.
Flinn RJ, Yan Y, Goswami S, Parker PJ, Backer JM. Flinn RJ, et al. Mol Biol Cell. 2010 Mar 1;21(5):833-41. doi: 10.1091/mbc.e09-09-0756. Epub 2010 Jan 6. Mol Biol Cell. 2010. PMID: 20053679 Free PMC article. - Targeting mTORC1 Activity to Improve Efficacy of Radioligand Therapy in Cancer.
Grzmil M, Wiesmann F, Schibli R, Behe M. Grzmil M, et al. Cancers (Basel). 2022 Dec 20;15(1):17. doi: 10.3390/cancers15010017. Cancers (Basel). 2022. PMID: 36612012 Free PMC article. Review. - Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer.
Rinne N, Christie EL, Ardasheva A, Kwok CH, Demchenko N, Low C, Tralau-Stewart C, Fotopoulou C, Cunnea P. Rinne N, et al. Cancer Drug Resist. 2021 Apr 14;4(3):573-595. doi: 10.20517/cdr.2021.05. eCollection 2021. Cancer Drug Resist. 2021. PMID: 35582310 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous